Literature DB >> 3012190

Combined pituitary function-test with four hypothalamic releasing hormones.

J Schopohl, M Losa, A König, O A Müller, G K Stalla, K von Werder.   

Abstract

Anterior pituitary function was investigated in ten healthy subjects by administering a combination of 200 micrograms thyrotropin releasing hormone (TRH), 100 micrograms gonadotropin releasing hormone (GnRH), 100 micrograms growth hormone releasing factor (GRF1-44), and 100 micrograms human corticotropin releasing factor (CRF). The same test protocol was performed in all subjects after pretreatment with 0.25 mg terguride. Five subjects were tested only with TRH and GnRH, five only with CRF, and six only with GRF. There was a prompt increase in all hormones after the administration of the four releasing hormones (RH). Pretreatment with terguride lowered the prolactin (PRL) increase (p less than 0.01) as well as the thyrotropin (TSH) peak (p less than 0.05) compared with the test without dopamine agonist pretreatment. The PRL levels after combined RH administration were significantly higher than after TRH and GnRH alone. Although four of the five subjects had higher TSH levels after combined RH administration than after TRH and GnRH alone, the difference was not significant. Other hormones were not significantly influenced by the combined RH administration or dopamine agonist pretreatment. Despite the fact that the interaction of the different releasing hormones and dopamine agonists influences the pituitary hormone response, combined RH administration seems to be a useful test for evaluating pituitary function also in patients receiving dopamine agonist therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012190     DOI: 10.1007/bf01711949

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  14 in total

1.  [Global pituitary stimulation test with releasing hormones].

Authors:  R Holl; H L Fehm; W D Hetzel; E Heinze; K H Voigt
Journal:  Dtsch Med Wochenschr       Date:  1985-06-14       Impact factor: 0.628

2.  Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSH-RH, TRH and hypoglycaemia alone and in combination.

Authors:  C H Mortimer; G M Besser; A S McNeilly; W M Tunbridge; A Gomez-Pan; R Hall
Journal:  Clin Endocrinol (Oxf)       Date:  1973-10       Impact factor: 3.478

3.  Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report.

Authors:  E Del Pozo; H Friesen; P Burmeister
Journal:  Schweiz Med Wochenschr       Date:  1973-06-09

4.  Multiple stimulation of the adenohypophysis by combinations of hypothalamic releasing factors.

Authors:  W B Wehrenberg; A Baird; S Y Ying; C Rivier; N Ling; R Guillemin
Journal:  Endocrinology       Date:  1984-06       Impact factor: 4.736

5.  The development of a direct homologous radioimmunoassay for serum cortisol.

Authors:  G K Stalla; G Giesemann; O A Müller; W G Wood; P C Scriba
Journal:  J Clin Chem Clin Biochem       Date:  1981-07

6.  The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin. I. In control subjects.

Authors:  F C Greenwood; J Landon; T C Stamp
Journal:  J Clin Invest       Date:  1966-04       Impact factor: 14.808

7.  Growth hormone releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients.

Authors:  K von Werder; O A Müller; R Hartl; M Losa; G K Stalla
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

8.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.

Authors:  R Guillemin; P Brazeau; P Böhlen; F Esch; N Ling; W B Wehrenberg
Journal:  Science       Date:  1982-11-05       Impact factor: 47.728

9.  Ovine (o) and human (h) corticotrophin releasing factor (CRF) in man: CRF-stimulation and CRF-immunoreactivity.

Authors:  G K Stalla; J Hartwimmer; K von Werder; O A Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1984-07

10.  Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene.

Authors:  S Shibahara; Y Morimoto; Y Furutani; M Notake; H Takahashi; S Shimizu; S Horikawa; S Numa
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  4 in total

1.  Pharmacokinetics and endocrine effects of terguride in healthy subjects.

Authors:  W Krause; H Träger; G Kühne; N Sauerbrey; K J Gräf; R Dorow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Interaction of L-dopa and GHRH on GH secretion in normal men.

Authors:  J Alba-Roth; C von Creytz; G Mehltretter; J Schopohl; O A Müller; K von Werder
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

3.  Effects of atrial natriuretic factor on anterior pituitary hormone secretion in normal man.

Authors:  M Kentsch; R Lawrenz; P Ball; R Gerzer; G Müller-Esch
Journal:  Clin Investig       Date:  1992-07

4.  The effect of GHRH on TSH release in rats in vivo and in vitro.

Authors:  B J Looij; A C Nieuwenhuijzen Kruseman; F Roelfsema; D van der Heide; R P Hoogma; J P Schröder-van der Elst
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.